Joshua Smiley Sells 9,614 Shares of Zai Lab (NASDAQ:ZLAB) Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) insider Joshua Smiley sold 9,614 shares of the firm’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $20.39, for a total value of $196,029.46. Following the sale, the insider directly owned 120,619 shares of the company’s stock, valued at approximately $2,459,421.41. This trade represents a 7.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Zai Lab Price Performance

Shares of Zai Lab stock opened at $20.41 on Friday. Zai Lab Limited Unsponsored ADR has a 52 week low of $15.96 and a 52 week high of $44.34. The business’s fifty day simple moving average is $18.67 and its 200-day simple moving average is $21.75. The firm has a market cap of $2.30 billion, a PE ratio of -12.68 and a beta of 0.86.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings data on Saturday, February 14th. The company reported ($0.50) earnings per share (EPS) for the quarter. The business had revenue of $127.60 million for the quarter. Zai Lab had a negative return on equity of 22.81% and a negative net margin of 38.15%. As a group, equities analysts expect that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on ZLAB. Jefferies Financial Group upgraded shares of Zai Lab to a “strong-buy” rating in a research report on Monday, January 19th. Zacks Research cut shares of Zai Lab from a “hold” rating to a “strong sell” rating in a research report on Friday, January 23rd. JPMorgan Chase & Co. dropped their target price on shares of Zai Lab from $39.00 to $32.00 and set an “overweight” rating for the company in a report on Wednesday, March 18th. Cantor Fitzgerald cut their target price on Zai Lab from $55.00 to $37.00 and set an “overweight” rating on the stock in a research report on Friday, February 27th. Finally, UBS Group initiated coverage on Zai Lab in a research note on Wednesday, January 7th. They set a “buy” rating and a $35.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Zai Lab presently has an average rating of “Moderate Buy” and an average target price of $50.00.

Institutional Trading of Zai Lab

An institutional investor recently bought a new position in Zai Lab stock. SG Americas Securities LLC purchased a new position in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 9,754 shares of the company’s stock, valued at approximately $331,000. 41.65% of the stock is owned by institutional investors.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.